Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy

American Journal of Geriatric Cardiology

Volumn 17, Issue 1, 2008, Pages 27-36

  Cushman, William C ^a   Neutel, Joel M ^b   Saunders, Elijah ^c   Bakris, George L ^d   Ferdinand, Keith C ^e   Ofili, Elizabeth O ^f   Sowers, James R ^g   Madder, Robert ^h   Weber, Michael A ⁱ  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b Orange County Research Center   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Association of Black Cardiologists   (United States)

^f MOREHOUSE SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ARIZONA   (United States)

^h Tri State Medical Group   (United States)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; PLACEBO; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; IRBESARTAN; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; AGE; DRUG COMBINATION; HEALTH SURVEY; MIDDLE AGED; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 40949113795     PISSN: 10767460     EISSN: 1751715X     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2007.07317.x     Document Type: Article

References (43)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290:199-206.
2. Fields LE, Burt VL, Cutler JA. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004, 44:398-404.
3. Franklin SS, Jacobs MJ, Wong ND. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001, 37:869-874.
4. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med 1992, 152:56-64. for the, Multiple Risk Factor Intervention Trial Research Group
5. Klag MJ, Whelton PK, Randall BL. Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334:13-18.
6. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000, 85:251-255.
7. Benetos A, Thomas F, Bean K. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 2002, 162:577-581.
8. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264. SHEP Cooperative Research Group
9. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304:405-412. MRC Working Party
10. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993, 15:967-978.
11. Staessen JA, Fagard R, Thijs L. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757-764.
12. Gueyffier F, Bulpitt C, Boissel JP. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999, 353:793-796. INDANA Group
13. Hansson L, Lindholm LH, Ekbom T. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
14. Staessen JA, Gasowski J, Wang JG. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355:865-872.
15. Asmar R. Benefits of blood pressure reduction in elderly patients. J Hypertens Suppl 2003, 21(6):S25-S30.
16. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
17. Izzo JL, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000, 35:1021-1024.
18. Cushman WC, Ford CE, Cutler JA. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393-404.
19. Materson BJ, Reda DJ, Cushman WC. Results of combination anti-hypertensive therapy after failure of each of the components. J Hum Hypertens 1995, 9:791-796.
20. Chaudhry SI, Krumholz HM, Foody JM. Systolic hypertension in older persons. JAMA 2004, 292:1074-1080.
21. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000, 9(suppl):2-6.
22. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003, 9:324-332.
23. Taylor AA. Combination drug treatment of hypertension: have we come full circle. Curr Cardiol Rep 2004, 6:421-426.
24. Law MR, Wald NJ, Morris JK. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427.
25. Kochar M, Guthrie R, Triscari J. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999, 12:797-805.
26. Pool JL, Guthrie RM, Littlejohn TW. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998, 11:462-470.
27. Rosenstock J, Rossi L, Lin CS. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther 1998, 23:433-440.
28. Coca A, Calvo C, Sobrino J. Once-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther 2003, 25:2849-2864.
29. Howe P, Phillips P, Saini R. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Clin Exp Hypertens 1999, 21:1373-1396.
30. Raskin P, Guthrie R, Flack J. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999, 13:683-687.
31. Welsh L, Ferro A. Drug treatment of essential hypertension: the case for initial combination therapy. Int J Clin Pract 2004, 58:956-963.
32. Marino MR, Vachharajani NN. Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol 2002, 40:112-122.
33. Lacourcière Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther 2000, 22:1213-1224.
34. Neutel JM, Saunders E, Bakris GL. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/HCTZ in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005, 7:578-586.
35. O'Brien E, Mee F, Atkins N. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit 1996, 1:55-61.
36. Douglas JG, Bakris GL, Epstein M. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003, 163:525-541.
37. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(suppl 1):S1-S290. National Kidney Foundation
38. Standards of medical care in diabetes-2006. Diabetes Care 2006, 29(suppl 1):S4-S42. American Diabetes Association
39. Fleiss JL. Statistical Methods for Rates and Proportions 1981, 2nd ed., New York, NY, John Wiley & Sons
40. Bristol-Myers Squibb Sanofi-Synthelabo Partnership. January 27, 2006, http://www.avalide.com/, Avalide United States prescribing information, Accessed
41. Hansson L. 'Why don't you do as I tell you?' Compliance and antihypertensive regimens. Int J Clin Pract 2002, 56:191-196.
42. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999, 21:973-985.
43. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002, 62:443-462.